BiotechTube

Placebo + Rifaximin

ApprovedTerminated
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Hepatic Encephalopathy

Conditions

Hepatic Encephalopathy

Trial Timeline

Apr 3, 2013 → Feb 22, 2016

NCT ID
NCT01846663

About Placebo + Rifaximin

Placebo + Rifaximin is a approved stage product being developed by Bausch Health for Hepatic Encephalopathy. The current trial status is terminated. This product is registered under clinical trial identifier NCT01846663. Target conditions include Hepatic Encephalopathy.

What happened to similar drugs?

2 of 17 similar drugs in Hepatic Encephalopathy were approved

Approved (2) Terminated (4) Active (12)
✅RifaximinBausch HealthApproved
✅Rifaximin + LactuloseBausch HealthApproved
🔄cisplatin + gemcitabine hydrochlorideEli LillyPhase 3
🔄PhosphatidylcholineSanofiPhase 3
❌oxaliplatin (SR96669) + capecitabine + sorafenibSanofiPhase 3
🔄Givosiran + PlaceboAlnylam PharmaceuticalsPhase 3
🔄A4250 (odevixibat)IpsenPhase 3

Hype Score Breakdown

Clinical
20
Activity
0
Company
9
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01846663ApprovedTerminated

Competing Products

20 competing products in Hepatic Encephalopathy

See all competitors
ProductCompanyStageHype Score
ITF2357BiotrialPhase 1
19
GB1211 + PlaceboComac MedicalPhase 1/2
18
ACT-541468 25 mg + ACT-541468 25 mg (or 10 mg depending on interim results)IdorsiaPhase 1
23
OlomorasibEli LillyPhase 1
29
SimufilamCassava SciencesPhase 1
19
cisplatin + gemcitabine hydrochlorideEli LillyPhase 3
40
exatecan mesylateDaiichi SankyoPhase 2
35
DS-3201bDaiichi SankyoPhase 1
29
QuizartinibDaiichi SankyoPhase 1
29
QuizartinibDaiichi SankyoPhase 1
36
PexidartinibDaiichi SankyoPhase 1
29
Tivantinib + Tivantinib + Tivantinib + TivantinibDaiichi SankyoPhase 1
29
BocidelparAstellas PharmaPhase 1
29
fezolinetantAstellas PharmaPhase 1
29
enzalutamideAstellas PharmaPhase 1
29
ASP015KAstellas PharmaPhase 1
29
ASP2215Astellas PharmaPhase 1
29
BPN14770ShionogiPhase 1
29
S-217622ShionogiPhase 1
29
LemborexantEisaiPhase 1
29